The US food and drug administration perspective on cancer biomarker development

被引：141
|
作者：
Gutman, Steven
Kessler, Larry G.
机构：
[1] US FDA, Off In Vitro Diagnost Devices, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA
[2] US FDA, Off Sci, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA
[3] US FDA, Engn Labs, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA
来源：
NATURE REVIEWS CANCER | 2006年 / 6卷 / 07期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1038/nrc1911
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Despite the intense interest in biomarker development for cancer management, few biomarker assays for diagnostic uses have been submitted to the US Food and Drug Administration (FDA). What challenges must researchers overcome to bring cancer-detection technologies to the market and, therefore, into clinical use?
引用
收藏
页码：565 / 571
页数：8
相关论文
共 50 条
  • [1] The US Food and Drug Administration perspective on cancer biomarker development
    Steven Gutman
    Larry G. Kessler
    Nature Reviews Cancer, 2006, 6 : 565 - 571
  • [2] ON THE DEVELOPMENT OF ANTIFUNGAL AGENTS - PERSPECTIVE OF THE US FOOD-AND-DRUG-ADMINISTRATION
    WU, TC
    CLINICAL INFECTIOUS DISEASES, 1994, 19 : S54 - S58
  • [3] Biomarker qualification pilot process at the US food and drug administration
    Goodsaid, Federico
    Frueh, Felix
    AAPS JOURNAL, 2007, 9 (01): : E105 - E108
  • [4] Biomarker qualification pilot process at the US Food and Drug Administration
    Federico Goodsaid
    Felix Frueh
    The AAPS Journal, 9
  • [5] Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration Perspective
    Walker, Amanda J.
    Kim, Hyun
    Saber, Haleh
    Kluetz, Paul G.
    Kim, Geoffrey
    Pazdur, Richard
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 5 - 7
  • [6] Perspective of the US Food and Drug Administration on concomitant administration of Zostavax and Pneumovax
    Baylor, Norman W.
    VACCINE, 2011, 29 (48) : 8771 - 8771
  • [7] Adverse drug events in children: The US food and drug administration perspective
    Rodriguez, W
    Roberts, R
    Murphy, D
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (10): : 711 - 723
  • [8] US food and drug administration perspective on aquaculture drug residues.
    Oriani, JA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 215 : U50 - U51
  • [9] US Food and Drug Administration's perspective on aquaculture drug residues
    Oriani, JA
    XENOBIOTICS IN FISH, 1999, : 15 - 23
  • [10] When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective
    Huang, S-M
    Temple, R.
    Xiao, S.
    Zhang, L.
    Lesko, L. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (05) : 475 - 479
12345